醒脑静与纳洛酮在重型颅脑损伤后迁延性昏迷治疗中疗效分析.docVIP

醒脑静与纳洛酮在重型颅脑损伤后迁延性昏迷治疗中疗效分析.doc

此“医疗卫生”领域文档为创作者个人分享资料,不作为权威性指导和指引,仅供参考
  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
醒脑静与纳洛酮在重型颅脑损伤后迁延性昏迷治疗中疗效分析

醒脑静与纳洛酮在重型颅脑损伤后迁延性昏迷治疗中疗效分析   [摘要] 目的 探讨醒脑静与纳洛酮治疗重型颅脑损伤后迁延性昏迷患者的疗效。 方法 分析我院2011年1月~2013年1月收治的76例重型颅脑损伤后迁延性昏迷患者,随机分为对照组36例、治疗组40例。两组均给予常规治疗,对照组在此基础上加用纳洛酮,治疗组在此基础上加用醒脑静。比较两组临床疗效、生命体征、格拉斯哥昏迷量表(GCS)评分、远期生活质量评估量表(KPS)评分的变化。 结果 对照组与治疗组临床总有效率分别为58.4%与82.5%,对照组呼吸系统与心血管系统异常发生率显著高于治疗组,对照组GCS评分与KPS评分均显著低于治疗组,两组比较差异均有统计学意义(P 0.05)。 结论 醒脑静与纳洛酮比较,在提高重型颅脑损伤后迁延性昏迷患者的临床治疗治愈率、减少呼吸及心脑血管事件的发生率及改善GCS评分与KPS评分均具有显著性意义,具有临床应用推广的价值。   [关键词] 重型颅脑损伤;迁延性昏迷;醒脑静;纳洛酮   [中图分类号] R651.1+5 [文献标识码] B [文章编号] 1673-9701(2014)11-0045-03   [Abstract] Objective To explore the effect of naloxone and Xingnaojing in the treatment of patients with persisting coma after severe craniocerebral injury. Methods A total of 76 patients of persisting coma after severe craniocerebral trauma of our hospital from January 2011 to January 2013 were analyzed and divided into the control group(36 cases),which used naloxone based on the conventional treatment, and the treatment group(40 cases), which used Xingnaojing injection based on the conventional treatment. The clinical curative effect, vital signs, Glasgow Coma Scale (GCS) score, the changes of long term quality of life assessment scale (KPS) score of two groups were compared. Results The total clinical effective rates of two groups were 58.4% and 82.5%. The respiratory and cardiovascular system abnormal rates of the control group were significantly higher than that in the treatment group. The GCS score and KPS score of control group were significantly lower than the treatment group. The comparison between two groups was statistically significant(P 0.05). Conclusion Xingnaojing can improve the clinical treatment of patients with persisting coma after severe craniocerebral injury compared with naloxone, reduce the incidence of respiratory and cardiovascular and cerebrovascular diseases, improve the GCS score and KPS score significantly and it is worthy of clinical application.   [Key words] Severe craniocerebral injury; Persistent coma; Xingnaojing injection; Nal

文档评论(0)

130****9768 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档